BioVie (BIVI) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

BIVI BioVie

Watchlist

2.710
-0.110-3.90%

Close Nov 27 16:00 ET

2.700
-0.010-0.37%

Post 20:01 ET

48.15MMarket Cap-533P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

BioVie Files to Sell 7.71M Shares of Common Stock for Holders
TipRanksNov 21 17:35 ET
BioVie to Present Design of Planned Phase 2 Study of Bezisterim for the Treatment of Long COVID at the Demystifying Long COVID International Conference
GlobeNewswireNov 20 08:00 ET
BioVie | 10-Q: Q1 2025 Earnings Report
SECNov 13 16:52 ET · Announcements
Express News | BioVie Inc - Pd-202 Trial Expected to Start Early 2025, Results by Late 2025
ReutersNov 4 08:00 ET
BioVie's Upcoming Parkinson's Disease Clinical Trial Is Fully Funded
Yahoo FinanceNov 4 08:00 ET
Express News | Biovie’s Upcoming Parkinson’s Disease Clinical Trial Is Fully Funded
ReutersNov 4 08:00 ET

Comments

Jaguar8

Nov 20 07:07

NEWS

$BioVie (BIVI.US)$
BioVie to Present Design of Planned Phase 2 Study of Bezisterim for the Treatment of Long COVID at the Demystifying Long COVID International Conference
BioVie (NASDAQ: BIVI) announced the acceptance of an abstract detailing their planned Phase 2 trial of bezisterim for Long COVID treatment at the Demystifying Long COVID International Conference in Barcelona. The study, fully funded by the U.S. Department of Defense, will be a double-blind, randomized, placebo-controlled tri...